Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Expert Shares Insight on Napabucasin Plus Pembrolizumab in mCRC

February 1st 2018

Akihito Kawazoe, MD, discusses the study of napabucasin plus pembrolizumab in mCRC.

Dr. Ramirez Discusses Treating Patients With NETs of the Lung

January 31st 2018

Robert Ramirez, DO, FACP, Ochsner Medical Center, discusses treating patients with neuroendocrine tumors (NETs) of the lung.

Immunotherapy Active in Advanced GISTs

January 31st 2018

Arun S. Singh, MD, discusses the developing role of immunotherapy in patients with GISTs, particularly the randomized phase II trial investigating nivolumab as a single agent and in combination with ipilimumab.

Dr. Kardosh Discusses Epacadostat in Gastric/GEJ Adenocarcinoma

January 30th 2018

Adel Kardosh, MD, postdoctoral medical fellow, oncology, Stanford Medicine, discusses epacadostat in gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Zhu Discusses Findings of the KEYNOTE-224 in HCC

January 30th 2018

Andrew Zhu, MD, PhD, director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the findings of KEYNOTE-224 in hepatocellular carcinoma (HCC).

Dr. Karasic on Palbociclib in Esophageal and Gastric Cancer

January 30th 2018

Thomas Karasic, MD, investigator at Penn Medicine, discusses the rationale behind the phase II trial (NCT01037790) of palbociclib (Ibrance) in patients with advanced esophageal or gastric cancer.

Entrectinib Effective in Pancreatic Cancer Subgroup

January 29th 2018

Michael J. Pishvaian, MD, PhD, discusses the findings with entrectinib in this population, as well as the potential implications of widespread molecular testing in pancreatic cancer.

Dr. Janjigian on Immunotherapy in Esophageal and Gastric Cancer

January 26th 2018

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with gastric and esophageal cancer.

FDA Approves Lutathera for GEP-NETs

January 26th 2018

The FDA has approved Lutathera for the treatment of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Dr. Singh Discusses Immunotherapy Study in GIST

January 26th 2018

Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

Dr. Andre on Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC

January 25th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the results of the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

Radiofrequency Ablation Improves Survival Over SBRT in Localized HCC

January 24th 2018

Radiofrequency ablation was associated with superior 5-year overall survival compared with stereotactic body radiotherapy for patients with localized hepatocellular carcinoma.

Nivolumab Alone or With Ipilimumab Provides Durable Benefit in MSI-H/dMMR mCRC

January 24th 2018

Data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

Dr. Overman Discusses Nivolumab in Patients With dMMR/MSI-H mCRC

January 24th 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses nivolumab (Opdivo) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic CRC.

Older CRC Patients at Increased Risk for New-Onset Cardiotoxicity

January 23rd 2018

Older patients with colorectal cancer are more likely to develop cardiovascular disease and congestive heart failure, according to results from an analysis of the SEER database.

Napabucasin Plus Pembrolizumab Shows Early Promise in mCRC

January 23rd 2018

Combining the investigational oral cancer stem cell pathway inhibitor napabucasin with the PD-1 inhibitor pembrolizumab showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.

Dr. Chau on the Tolerability of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer

January 23rd 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

Dr. Bekaii-Saab Discusses QoL With Regorafenib Dose Escalation in mCRC

January 23rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the quality of life findings for a dose-escalation study of regorafenib (Stivarga) in metastatic colorectal cancer.

Dr. Ilson Discusses the Optimal Adjuvant Therapy for Resectable Gastric Cancer

January 22nd 2018

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a trial from Germany comparing standard perioperative ECF/ECX chemotherapy with a regimen combining 5-FU (5-fluorouracil) with oxaliplatin and docetaxel.

Pembrolizumab Promising After Sorafenib in Advanced HCC

January 21st 2018

Treatment with the PD-1 inhibitor pembrolizumab elicited promising progression-free survival and overall survival results in patients with advanced hepatocellular carcinoma who received previous treatment with sorafenib.